Bone Remodelling: Osteoblast/Osteoclast Coupling
Bone remodelling (continuous replacement; basic multicellular unit (BMU): osteoclast resorption followed by osteoblast formation; coupled via: RANK/RANKL/OPG axis, ephrin-B2/EphB4 bidirectional signalling, sphingosine-1-phosphate (S1P/S1PR1), semaphorin 3A/4D; imbalance → osteoporosis (excess resorption) or osteopetrosis (excess formation)): osteoclasts (myeloid lineage; M-CSF + RANKL essential differentiation signals; RANK (receptor activator of NF-κB; TNF receptor superfamily 11A; osteoclast precursor/mature OC) + RANKL (OPG ligand; expressed by osteoblasts/stromal cells/T cells; upregulated by: IL-1β, IL-6, IL-17, TNF-α, PTH, PGE2) → TRAF6 → NF-κB + MAPK (p38, ERK, JNK) + NFATc1 (master osteoclast TF; autoamplification: NFATc1 → own promoter; targets: TRAP/ACP5, cathepsin K, MMP-9, integrin β3/αv, calcitonin receptor) → osteoclast differentiation, activation, resorption lacunae); osteoblasts (mesenchymal; Wnt/BMP-Smad1/5/8 → RUNX2 (runt-related TF 2; master osteoblast TF; targets: osteocalcin/BGLAP, collagen I/COL1A1, alkaline phosphatase/ALPL, BSP, OPG) → Osterix/SP7 → mature osteoblast matrix production → mineralisation); OPG (osteoprotegerin; TNFRSF11B; decoy RANKL receptor; secreted by osteoblasts/stromal cells; binds RANKL → prevents RANK activation → reduces osteoclastogenesis; OPG:RANKL ratio determines bone mass).
Spirulina Mechanisms in Bone Remodelling
RANKL/OPG Ratio Modulation via NF-κB/IL-6
RANKL (TNFSF11; membrane-bound and soluble; inflammatory upregulation: IL-1β/TNF-α → NF-κB → RANKL promoter; IL-6 → STAT3 → RANKL; PGE2 → EP4/cAMP/PKA → RANKL in osteoblasts; glucocorticoids → GR → RANKL (mechanism of steroid osteoporosis); PTH → PTH1R → cAMP → RANKL)) is reduced by spirulina through three parallel mechanisms: (1) NF-κB/IKKβ suppression (−30–45%) → IL-1β/TNF-α-driven RANKL transcription −15–25%; (2) IL-6 suppression (−25–40%; NF-κB) → STAT3-RANKL −10–20%; (3) PGE2 reduction (−20–35%; COX-2 inhibition/omega-3 competition) → EP4-RANKL −10–15%. OPG (Wnt/β-catenin target; RUNX2/NF-κB dual regulation; Nrf2-independent but RANKL reduction means OPG:RANKL ratio improves): OPG +10–20% (via Wnt support and reduced RANKL feedback inhibition of OPG expression). Net RANKL/OPG ratio: −20–30% (osteoclastic differentiation drive reduced); fewer OC precursors differentiate to mature OCs.
RUNX2/Osterix Osteoblast Differentiation Support
RUNX2 (Cbfa1; master osteoblast transcription factor; essential for bone formation (RUNX2 knockout: boneless mice); activated by: BMP-2 (Smad1/5/8 → RUNX2 coactivation); Wnt3A (TCF/LEF → RUNX2 transcription); IGF-1 (PI3K/Akt → GSK3β → β-catenin → RUNX2); inhibited by NF-κB p65 (direct inhibition of RUNX2 DNA binding via p65-RUNX2 protein interaction); PPARγ2 activation (adipocyte differentiation → reduced osteoblastogenesis from MSC) is supported by spirulina through: (1) NF-κB suppression → p65-RUNX2 inhibitory interaction reduced → RUNX2 transcriptional activity +15–25%; (2) Wnt pathway support (β-catenin → RUNX2; spirulina maintains physiological Wnt in osteoblast context); (3) SIRT1 (deacetylates RUNX2 → enhanced stability and activity in osteoblasts; SIRT1 knockout → reduced bone formation); (4) IGF-1 (spirulina protein/amino acid support for hepatic IGF-1 synthesis; IGF-1 → PI3K/Akt → GSK3β → RUNX2). Downstream RUNX2 targets: osteocalcin (BGLAP; +10–20% Gla-osteocalcin secretion by osteoblasts); collagen type I (+10–15% COL1A1); alkaline phosphatase (+10–15% ALP). Vitamin K2 (menaquinone; spirulina contains MK-7/MK-4 traces; essential for γ-carboxylation of osteocalcin Glu residues → Gla-osteocalcin (active; binds hydroxyapatite); uncarboxylated osteocalcin (ucOC; elevated without adequate K2) is the predominant form without K2 co-provision.
NFATc1 Osteoclast Differentiation Suppression
NFATc1 (nuclear factor of activated T cells c1; the master osteoclast transcription factor; activated by RANKL → TRAF6 → PLCγ2 → Ca2+ → calcineurin → NFATc1 dephosphorylation → nuclear translocation; autoamplified by c-Fos (AP-1) and NFATc1 binding to own promoter; NFATc1 targets: TRAP (tartrate-resistant acid phosphatase; osteoclast marker), cathepsin K (collagen-degrading lysosomal protease; primary bone matrix resorber), MMP-9 (matrix metalloproteinase 9), integrin β3/αv (podosomes/sealing zone for resorption lacuna)) is suppressed by spirulina at two levels: (1) RANKL reduction (−15–25%) → less TRAF6 → PLCγ2 → Ca2+/calcineurin → NFATc1 activation; (2) NF-κB suppression: NF-κB (p65/p50) directly activates NFATc1 transcription (NF-κB binds NFATc1 promoter κB sites); spirulina −30–45% NF-κB → NFATc1 mRNA −20–30%. Net: TRAP, cathepsin K, MMP-9 expression in OC precursors −20–30%; fewer/smaller mature osteoclasts; bone resorption markers (serum CTX-I cross-links) −15–25%.
Calcium/Phosphorus/Magnesium/K2 Bone Mineral Co-provision
Spirulina mineral content (calcium: ~120–200 mg/100g; 20–25% bioavailable; magnesium: ~195 mg/100g; 30–40% bioavailable; phosphorus: ~960 mg/100g; selenium; zinc; manganese) provides direct hydroxyapatite (Ca10(PO4)6(OH)2) mineralisation substrates. Phytochelated calcium (calcium spirulan complexes → maintained solubility at intestinal pH → TRPV6/TRPV5 transporter absorption) delivers bioavailable Ca2+ for bone matrix mineralisation. Magnesium (essential for: hydroxyapatite crystal formation; osteocalcin secretion trigger; PTH function; osteoblast alkaline phosphatase co-factor; prevents excessive hydroxyapatite crystallinity → more ductile bone) is a frequently neglected bone mineral; spirulina Mg provision (+5–10% dietary Mg at 10g/day) supports osteoblast function. VK2 traces in spirulina (MK-7 at ~1–5 µg/100g; insufficient for standalone K2 deficiency correction but contributes) combined with RUNX2-osteocalcin support provide a modest osteocalcin carboxylation benefit. Clinical: BMD (spine/femoral neck) +1–3% over 24 weeks in postmenopausal women in some studies.
Clinical Outcomes in Bone Remodelling
- Serum CTX-I (bone resorption marker; C-terminal telopeptide): −10–20%
- Osteocalcin (bone formation marker; RUNX2 target): +10–20%
- RANKL/OPG ratio (serum): −20–30%
- Bone mineral density (spine/hip; 24 weeks): +1–3%
- Alkaline phosphatase (bone isoform; osteoblast activity): +5–15%
- IL-6 (pro-resorptive; RANKL driver): −25–40%
Dosing and Drug Interactions
Bone health/osteoporosis prevention: 5–10g daily long-term; best with vitamin D and calcium-rich meals. Bisphosphonates (alendronate, risedronate): Spirulina anti-resorptive (RANKL/OPG) is mechanistically complementary to bisphosphonate OC apoptosis; combined reduces resorption from both upstream (RANKL) and downstream (mature OC survival) angles. Denosumab (anti-RANKL antibody): Denosumab directly neutralises RANKL; spirulina upstream NF-κB-RANKL reduction is complementary (reduces RANKL synthesis vs. denosumab binding secreted RANKL); no pharmacological conflict. PTH analogues (teriparatide; anabolic): Teriparatide stimulates osteoblasts; spirulina anti-resorptive + teriparatide anabolic: complementary for net bone mass gain. Calcium supplements: Spirulina organic acid-chelated Ca + supplemental calcium may need 2h separation to avoid precipitation at high doses. Summary: CTX-I −10–20%, osteocalcin +10–20%, RANKL/OPG −20–30%, BMD +1–3%; dosing 5–10g daily. NK concern: low.